AU2001244216A1 - Identification of mast cell/basophil activation inhibitors - Google Patents

Identification of mast cell/basophil activation inhibitors

Info

Publication number
AU2001244216A1
AU2001244216A1 AU2001244216A AU4421601A AU2001244216A1 AU 2001244216 A1 AU2001244216 A1 AU 2001244216A1 AU 2001244216 A AU2001244216 A AU 2001244216A AU 4421601 A AU4421601 A AU 4421601A AU 2001244216 A1 AU2001244216 A1 AU 2001244216A1
Authority
AU
Australia
Prior art keywords
identification
mast cell
basophil activation
activation inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244216A
Other languages
English (en)
Inventor
Franz Kricek
Andreas Nechansky
Michael Robertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001244216A1 publication Critical patent/AU2001244216A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001244216A 2000-03-23 2001-03-22 Identification of mast cell/basophil activation inhibitors Abandoned AU2001244216A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19167000P 2000-03-23 2000-03-23
US60/191,670 2000-03-23
PCT/EP2001/003267 WO2001071342A2 (en) 2000-03-23 2001-03-22 Identification of mast cell/basophil activation inhibitors

Publications (1)

Publication Number Publication Date
AU2001244216A1 true AU2001244216A1 (en) 2001-10-03

Family

ID=22706437

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244216A Abandoned AU2001244216A1 (en) 2000-03-23 2001-03-22 Identification of mast cell/basophil activation inhibitors

Country Status (5)

Country Link
US (1) US20030166568A1 (de)
EP (1) EP1269198A2 (de)
JP (1) JP2003528317A (de)
AU (1) AU2001244216A1 (de)
WO (1) WO2001071342A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511771D0 (en) 2005-06-09 2005-07-20 Novartis Ag Organic compounds
ITMI20061607A1 (it) * 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912092A (en) * 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
CA2059842A1 (en) * 1991-02-11 1992-08-12 Richard A. Chizzonite Ige-receptor-antibodies
DE69841711D1 (de) * 1997-03-25 2010-07-22 Duska Scient Co Modulator der menschlichen mastzellaktivierung

Also Published As

Publication number Publication date
US20030166568A1 (en) 2003-09-04
EP1269198A2 (de) 2003-01-02
WO2001071342A2 (en) 2001-09-27
WO2001071342A3 (en) 2002-08-29
JP2003528317A (ja) 2003-09-24

Similar Documents

Publication Publication Date Title
AU2002258941A1 (en) Methods of enhancing cell responsiveness
AU2001258771A1 (en) -secretase inhibitors
AU2002317418A1 (en) Cell enumeration
AU2001237041A1 (en) Kinase inhibitors
AU2001293373A1 (en) 2-guanidino-4-arylchinazolines as NHE-3 inhibitors
AU2548699A (en) Cell death inhibitors
AU2001294557A1 (en) Thrombin inhibitors
AU2001288360A1 (en) Genomics-assisted rapid identification of targets
AU2001244596A1 (en) Indolylpyrrole derivatives and cell death inhibitors
AU2002222627A1 (en) Tak1 inhibitors
AU2001241917A1 (en) Myt1 kinase inhibitors
AU2002219900A1 (en) Minimal identification of features
AU2002213164A1 (en) Detection of dna damage
AU2003235122A1 (en) Cell death inhibitor
AU2002316552A1 (en) Inhibitor of t cell activation
AU2002214038A1 (en) Inhibitors of transglutaminases
AUPS233702A0 (en) Identification of eukaryotic species
AU2001295966A1 (en) Cell damage inhibitor
AU2001244216A1 (en) Identification of mast cell/basophil activation inhibitors
AU2001236624A1 (en) Rapid, parallel identification of cell lines
AU2001278997A1 (en) Thrombin inhibitors
AU2002224835A1 (en) Dihydroisoquinolines as novel phosphodiesterase inhibitors
AU3595900A (en) Tyrosine alkoxyguanidines as integrin inhibitors
EP1437142A4 (de) Mittel zur hemmung des zellwachstums
AU2001233965A1 (en) Novel cd23 inhibitors